ESSEXBIO-TECH：ANNUALREPORT2020.pdf

1、2020 AnnualReport20202020年報ANNUAL REPORT年 報CONTENTS CONTENTS2Chairmans Statement10Business Review20Financial Highlights21Financial Review28Profiles of Directors and Senior Management31Report of the Directors52Independent Auditors Report57Consolidated Statement of Profit or Loss and Other Comprehensi

2、ve Income58Consolidated Statement of Financial Position 59Consolidated Statement of Changes in Equity60Consolidated Statement of Cash Flows62Notes to the Consolidated Financial Statements130Five Year Financial Summary131Corporate Governance Report142Corporate Information CHAIRMANS STATEMENT ESSEX BI

3、O-TECHNOLOGY LIMITEDAnnual Report 20202Ngiam Mia Je PatrickChairmanESSEX BIO-TECHNOLOGY LIMITEDAnnual Report 20203 CHAIRMANS STATEMENT 2020 has been a challenging year,an unprecedented year.The impact from the outbreak of the novel coronavirus(“COVID-19”)was in ways we never had imagined.During the

4、year under review,COVID-19 has negatively impacted our financial results and caused delay in ongoing clinical trial programmes.However,in these demanding times,leadership,team spirits and acting responsibly have become the most critical value to be resilient and allowed us to continue executing our

5、plans.FINANCIAL PERFORMANCEFor the year ended 31 December 2020,Essex Bio-Technology Limited(the“Company”,together with its subsidiaries,the“Group”)achieved a consolidated turnover of approximately HK$978.1 million,a decrease of 23.6%over the last year.The decrease is attributable to about 44.3%decre

6、ase in the first half of 2020 as the government implemented a series of control measures in a number of provinces and municipalities in the Peoples Republic of China(the“PRC”)to curb the spread of COVID-19,which had significantly disrupted the clinical operations of hospitals in the PRC and had prev